Palisade Bio, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical issuer developing oral PDE4 inhibitor prodrugs. Disclosures include proxy materials for annual and special stockholder meetings, director elections, auditor ratification, charter-amendment voting matters and compensation-plan governance.
Material-event reports and registration statements cover clinical-development service arrangements, common-stock sales, securities registration, capital-structure updates, Nasdaq listing compliance and meeting adjournment or withdrawal actions. The filings also provide formal context for PALI-2108 development activities, equity financing mechanics, corporate governance and public-company reporting obligations.
Palisade Bio, Inc. beneficial ownership update: Commodore Capital reports beneficially owning 12,366,776 shares of Common Stock as of March 31, 2026, equal to 7.2% based on 167,421,702 shares reported outstanding. The total includes 5,185,714 shares issuable upon exercise of a Pre-Funded Warrant, which is subject to a 9.99% Beneficial Ownership Limitation.
Palisade Bio, Inc. receives a Schedule 13G/A reporting a 7.9% beneficial ownership stake held collectively by Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund.
The filing states the Reporting Persons share voting and dispositive power over 14,113,863 shares of Common Stock. The ownership percentages are calculated using 173,579,670 shares outstanding as of May 7, 2026 and assume exercise of 5,185,714 Pre-Funded Warrants subject to a 9.99% Beneficial Ownership Limitation.
Palisade Bio, Inc. reported institutional holdings disclosed on a Schedule 13G. Ameriprise Financial, Inc. and its affiliate Columbia Management Investment Advisers, LLC report shared voting and dispositive power over 8,711,385 shares, representing 5.3% of the class as shown on the cover page.
The filing states AFI is the parent of CMIA and includes CMIA's reported holdings; both entities disclaim beneficial ownership. Signature and exhibit references identify a subsidiary and a joint filing agreement.
Palisade Bio, Inc. filed a shelf registration on to offer up to $300,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The prospectus describes general terms; specific amounts, prices and offering methods will be provided in future prospectus supplements. The filing notes completed Phase 1/1b clinical programs for lead candidate PALI-2108, reporting dosing of 89 subjects across healthy volunteer and UC cohorts and five FSCD patients in an exploratory cohort, with company statements of favorable safety, tolerability, pharmacokinetics and pharmacodynamic target engagement. The company states plans for IND submissions and to initiate a Phase 2 UC trial in Q3 2026. The prospectus discloses governance, capitalization, outstanding derivative instruments, and routine risk factors related to development, regulatory approval and financing.
Palisade Bio reported first quarter 2026 results and highlighted progress of its lead IBD candidate, PALI-2108. The company completed Phase 1a/1b studies with favorable safety, target engagement in ileum and colon tissue, and early clinical activity, and is preparing Phase 2 trials in ulcerative colitis and Crohn’s disease starting in 3Q 2026 and 1Q 2027, respectively.
Research and development expenses rose to $6.4 million and general and administrative expenses to $4.4 million, driving a net loss of $9.6 million for the quarter. Palisade ended March 31, 2026 with $132.6 million in cash and cash equivalents and expects this to fund operations through Phase 2 efficacy readouts for PALI-2108 in 2027 and early 2028.
Palisade Bio, Inc. reported a larger quarterly loss as it ramps development of its lead IBD drug candidate, but ended the period with substantial cash. For the three months ended March 31, 2026, net loss widened to $9.6 million from $2.2 million a year earlier, driven by higher research and development and general and administrative spending. Research and development expenses rose to $6.4 million, reflecting increased clinical trial and manufacturing activity for PALI-2108 and higher stock-based compensation. General and administrative costs increased to $4.4 million, also largely from stock-based compensation and higher legal fees. The company generated $1.1 million of other income from money market investments following a large equity raise in 2025. Palisade ended the quarter with $132.6 million in cash, cash equivalents and restricted cash and believes this will fund key Phase 2 trials through efficacy readouts in ulcerative colitis and Crohn’s disease. Management still reports a material weakness in internal control over financial reporting and is pursuing remediation.
Palisade Bio, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on director elections, auditor ratification, major share authorization changes, and updated equity plans. The meeting will be held online on June 10, 2026, and only stockholders of record as of April 15, 2026 may vote.
Proposals include electing four directors, ratifying Baker Tilly US, LLP as auditor for 2026, and amending the certificate of incorporation to increase authorized common stock from 300,000,000 to 450,000,000 shares. As of the record date, 167,424,202 common shares were outstanding, with significant additional shares reserved for warrants, options and equity awards.
Stockholders are also asked to approve an amended 2021 Equity Incentive Plan with a fixed pool of 42,257,000 shares and an amended Employee Stock Purchase Plan authorizing 837,000 shares, along with advisory say-on-pay and non‑employee director grant proposals. All proposals require various majority vote standards, and brokers will have discretion only on the auditor and authorized share increase items.
Palisade Bio, Inc. is soliciting proxies for its 2026 virtual Annual Meeting of Stockholders to elect four directors and seek approval for seven proposals, including an increase in authorized common stock, an amended equity incentive plan, and an amended employee stock purchase plan. As of the Record Date (April 15, 2026), there were 167,424,202 shares outstanding.
The Board asks stockholders to approve amending the Certificate of Incorporation to increase authorized common shares from 300,000,000 to 450,000,000, to approve an Amended and Restated 2021 Equity Incentive Plan reserving 42,257,000 shares, and to approve an Amended and Restated ESPP reserving 837,000 shares. The proxy materials also describe equity overhang from warrants, options and pre-funded warrants and note the company raised approximately $138.0M in an October 2025 financing.
Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc. d/b/a Iterative Health to help enroll patients in its planned Phase 2 study of PALI-2108 for moderate to severe ulcerative colitis. To support this collaboration, the company issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health for a total of $3.0 million, at $1.952 per share, which matches the average closing price over the five trading days before the closing date. The shares were sold in a private transaction exempt from registration under Section 4(a)(2) of the Securities Act of 1933.